IP Library Granted Patent US 8,466,269
Granted Patent B2
US 8,466,269 · App. 13/435,970 · Granted Jun 18, 2013

Covalent tethering of functional groups to proteins and substrates therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,466,269
App. No.
13/435,970
Granted
Jun 18, 2013
Kind
B2
Abstract

A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.

Claims (12)

1. An isolated polynucleotide encoding a mutant dehalogenase having at least 85% amino acid sequence identity to SEQ ID NO:82, and having at least two amino acid substitutions, the mutant dehalogenase capable of forming a bond with a dehalogenase substrate that is more stable than the bond formed between the dehalogenase of SEQ ID NO:82 and the substrate, wherein one substitution is at an amino acid residue corresponding to residue 272 of SEQ ID NO:82, and wherein a second substitution is at an amino acid residue corresponding to residue 273 of SEQ ID NO: 82.

2. The polynucleotide of claim 1 wherein the mutant dehalogenase has at least 90% amino acid sequence identity to SEQ ID NO: 82.

3. The polynucleotide of claim 1 wherein the amino acid at the position corresponding to residue 272 is phenylalanine, glycine or alanine.

4. The polynucleotide of claim 1 wherein the amino acid at position 273 is leucine, methionine or cysteine.

5. The polynucleotide of claim 1 further comprising a substitution at the position corresponding to amino acid residue 175.

6. The polynucleotide of claim 5 wherein the amino acid at position 175 is methionine, valine, glutamate, aspartate, alanine, leucine, serine or cysteine.

7. The polynucleotide of claim 1 further comprising a substitution at the position corresponding to amino acid residue 176.

8. The polynucleotide of claim 7 wherein the amino acid at the position corresponding to residue 176 is serine, glycine, asparagine, aspartate, threonine, alanine or arginine.

9. The polynucleotide of claim 1 further comprising an open reading frame for one or more proteins of interest, such that expression of the polynucleotide yields a fusion protein comprising the mutant dehalogenase and the protein of interest.

10. A method of expressing the polynucleotide of claim 1 in a host cell, comprising the step of transforming or transfecting the host cell with an expression vector comprising the polynucleotide of claim 1 wherein the polynucleotide is expressed and wherein the encoded mutant dehalogenase polypeptide is produced.

11. The method of claim 10 wherein the host cell is a bacterial cell.

12. The method of claim 10 wherein the host cell is a mammalian cell.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2012
From: DARZINS, ALDIS; ENCELL, LANCE; KLAUBERT, DIETER; LOS, GEORGYI V.; MCDOUGALL, MARK; WOOD, KEITH V.; WOOD, MONIKA G.; ZIMPRICH, CHAD
To: PROMEGA CORPORATION
Reel/Frame 028402/0092 →